Cingulate Inc

-0.05 (-5.37%)
Earnings Announcements

Cingulate Inc Reports Q3 Loss Of $0.36 Per Share

Published: 11/14/2022 13:04 GMT
Cingulate Inc (CING) - Cingulate Inc. Reports Third Quarter 2022 Financial Results and Provides Clinical and Business Update.
Cingulate Inc - Phase 3 Trial Initiation for Lead Adhd Candidate Ctx-1301 in December 2022.
Cingulate Inc - Qtrly Loss per Share $0.36.
Cingulate Inc - As of September 30, 2022, Cingulate Had $9.8 Million in Cash and Cash Equivalents.
Cingulate Inc - Upon Positive Clinical Results From Phase 3 Trials and Food Effect Study, Co Plans to Submit NDA for Ctx-1301 in First Half of 2024.
Cingulate Inc - Evaluating Alternatives to Raise Additional Capital, Including Equity and Debt Financing.
Cingulate Inc - Expects Cash and Cash Equivalents to Enable to Fund Research & Development & General & Administrative Expenditures Through Q1 of 2023.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.38

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.46

More details on our Analysts Page.